Balaxi Pharma To Invest Rs 85 Cr Manufacturing Facility In Hyderabad Plant

NSE listed Balaxi Pharmaceuticals will be investing Rs 85 crore in the state-of-the-art facility over a period of one year that will enable them to enter European markets as well as enhance margins in current markets.

The company performed the groundbreaking ceremony of its US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation Plant at Jadcherla Mandal, Telangana.

To drive this initiative forward, Spectrum Pharmatech Consultant has been appointed for the smooth and time bound project execution. Spectrum Pharmatech, Mumbai is the Design, Engineering, and Turnkey Execution Consultant for this project. 

The plant will provide direct and indirect employment to approximately 350+ individuals. This US-FDA, EU-GMP, WHO-Geneva Compliant Pharmaceutical Formulation facility is housed across approximately 1,50,000 square feet, with a capacity of 1 billion tablets per annum, 500 million capsules per annum, and 27 million liquid injections per annum.

The plant’s proposed completion is scheduled for March 2024 and will be abundantly equipped to cater to the demands of global markets. Adhering to global standards for products and services, production from its planned facility will find immediate traction from established demand in existing markets. The robust production will allow backward integration of its supply chain and is expected to start by June 2024.

Ashish Maheshwari, Managing Director, Balaxi Pharmaceuticals said, “For us, the plant commission in Telangana is much more than just a facility, it is a true milestone for Balaxi Pharmaceuticals that will enable us to move from semi regulated to regulated markets. Balaxi will establish a manufacturing ecosystem that affords better control, improves regulatory processes and reduces time to market for new product launches.”